Current Report Filing (8-k)
March 24 2021 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 10, 2021
CYCLACEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
0-50626
|
|
91-1707622
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
(Address of principal executive offices
and zip code)
Registrant’s telephone number,
including area code: (908) 517-7330
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
CYCC
|
|
The Nasdaq Stock Market LLC
|
Preferred Stock, $0.001 par value
|
|
CYCCP
|
|
The Nasdaq Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Declaration of Quarterly Cash Dividend
on 6% Convertible Exchangeable Preferred Stock
On March 10, 2021,
the Board of Directors (the “Board”) of Cyclacel Pharmaceuticals, Inc. (the “Company”) declared
a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock (“Preferred
Stock”). The cash dividend will be payable on May 1, 2021 to the holders of record of the Preferred Stock as of the close
of business on April 16, 2021.
The
Board considered numerous factors in determining whether to declare the quarterly dividend, including the requisite financial
analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future
quarters, there is no assurance that future quarterly dividends will be declared.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
CYCLACEL PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Paul McBarron
|
|
|
Name:
|
Paul McBarron
|
|
|
Title:
|
Executive Vice President—Finance,
|
|
|
|
Chief Financial Officer and Chief Operating Officer
|
|
Date: March 23,
2021
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2023 to Apr 2024